Introduction
============

Kidney transplantation offers a greater survival benefit compared to dialytic therapy in end-stage kidney disease (ESKD) patients;[@b1-ijnrd-11-187] however, a high prevalence of cardiovascular disease (CVD) among kidney transplant recipients (KTRs) predisposes them to increased mortality in comparison to healthy controls.[@b2-ijnrd-11-187],[@b3-ijnrd-11-187] Risk factors for vascular disease identified among KTRs in an American study included age, sex, cigarette smoking, pre-transplant splenectomy, and serum albumin.[@b4-ijnrd-11-187] Traditionally, a favorable lipid profile among black Africans was identified as the reason for a lower prevalence of atherosclerotic vascular disease (AsVD) and ischemic heart disease, despite the presence of other cardiovascular risk factors.[@b5-ijnrd-11-187] However, a rise has been reported in the prevalence of dyslipidemia and ischemic heart disease in the urban black population of South Africa.[@b6-ijnrd-11-187],[@b7-ijnrd-11-187] This trend has been attributed to increasing urbanization, changes in diet, and a reduction in physical activity.[@b8-ijnrd-11-187] Additionally, the high prevalence of both traditional and chronic kidney disease (CKD)-related cardiovascular risk factors among ESKD patients has contributed to the high risk of AsVD among this group of patients. A case--control study among black South African ESKD patients reported a higher prevalence of carotid plaques among ESKD patients on maintenance hemodialysis (38.1%) when compared with controls (7.9%).[@b9-ijnrd-11-187] Furthermore, Muhammad et al[@b10-ijnrd-11-187] found left ventricular hypertrophy (LVH) to be prevalent among KTRs and also reported that a longer duration on dialysis, cigarette smoking, higher cumulative steroid dose, increased carotid intima media thickness (CIMT), and increased waist circumference predicted the presence of LVH. In view of the aggressive use of lipid-lowering medications in CKD and post-kidney transplantation, use of conventional lipid profiles for cardiovascular risk assessment in this group of patients may not provide the whole picture. Lipoprotein ratios may correlate better with AsVD than lipid profile parameters. The discriminatory and predictive power of total cholesterol (TC)/high-density lipoprotein (HDL) was found to be superior to either TC or HDL.[@b11-ijnrd-11-187] Lipoprotein ratios have been shown to be superior to conventional lipid profiles in predicting coronary heart disease.[@b12-ijnrd-11-187] Furthermore, sociodemographic characteristics and possibly genetic variations may impact the cardiovascular risk among KTRs in our environment. Although some studies have evaluated CVD among black ESKD, maintenance dialysis, and renal transplant patients,[@b9-ijnrd-11-187],[@b10-ijnrd-11-187] a significant knowledge gap of the risk factors for AsVD among stable, black KTRs in the absence of diabetes and inflammatory conditions still exists.

In view of the paucity of knowledge about AsVD among black South African KTRs, we evaluated the relationship of dyslipidemia and lipoprotein ratios to AsVD among non-diabetic, stable, black KTRs.

Methods
=======

This was a comparative cross-sectional study of 41 adult (age 18--65 years) non-diabetic, stable KTRs and 41 age- and sex-matched healthy controls at a large urban public hospital in South Africa from January 2, 2017 to August 31, 2017. The study was approved by the Human Research Ethics Committee, University of Witwatersrand, Johannesburg, South Africa (Study number 160614). All participants provided signed informed consent before enrollment in the study. An interviewer-administered questionnaire was used to obtain information on the participants' sociodemographic and cardiovascular risk factors.

Waist and hip circumferences were measured with patients in an erect position and waist--hip ratios (WHR) calculated. Body mass index (BMI) was calculated using the formula mass/height[@b2-ijnrd-11-187], while body surface area was calculated using the Mosteller formula.[@b13-ijnrd-11-187] Serum fibrinogen was determined using STA-R Max (Stago, Asnièressur-Seine, France). A serum lipogram (TC, low-density lipoprotein \[LDL\], triglyceride \[TG\], HDL) was determined by an enzymatic colorimetric method using the Cobas 8000 modular analyzer series, module c701 analyzer (Hoffman-La Roche Ltd., Basel, Switzerland). Lipoprotein ratios were calculated as follows: atherogenic index of plasma = Log (TG/HDL); Castelli index 1 = TC/HDL; Castelli index 2 = LDL/HDL; non-HDL = TC-HDL; atherogenic index (AI) = non-HDL/HDL; lipoprotein combine index (LCI) = (TC × TG × LDL)/HDL.[@b14-ijnrd-11-187] The urine albumin--creatinine ratio was determined by an immunoturbidimetric assay, using a Tina-quint Albumin Gen.2 serum/plasma application kit, on the Cobas 8000 modular analyzer, module c502. Estimated glomerular filtration rate (eGFR) was calculated using the 2009 CKD-EPI formula.[@b15-ijnrd-11-187] All participants had echocardiography and CIMT measurements in accordance with the guidelines of the American Society of Echocardiography,[@b16-ijnrd-11-187] using a Philips iE33 echocardiography machine (Philips, Amsterdam, the Netherlands). CIMT was assessed using the vascular probe of the echocardiography machine, Philips IE33 (S5-1 probe) by focusing on the far wall of the common carotid artery, 1 cm proximal to the dilatation of the carotid bulb along the long axis of the artery. Automatic echo-generated measurements with percentage quality of 95% were recorded. The procedure was performed on both the left and right carotid arteries and the average used in analysis.

Data analysis
-------------

Stata version13.1 (StataCorp LP, College Station, TX, USA) was used for statistical analysis. Categorical variables were expressed as frequencies and percentages and compared using the chi-square test. A Shapiro--Wilk test of normality was performed on all continuous variables and normally distributed data were presented as mean ± SD, while non-normally distributed data were presented as median and interquartile range (IQR). Comparisons were performed between KTRs and controls, and between participants who had AsVD and those who did not, using the Student's *t*-test for normally distributed data and the Wilcoxon rank-sum test for non-normally distributed data.

Spearman's correlation was used to determine the relationship between CIMT and cardiovascular risk factors among KTRs and controls. Multivariate regression analysis was performed to determine the relationship and contribution of cardiovascular risk factors to AsVD. Significance was taken as *p*\<0.05. Post-regression analysis was performed to determine the goodness-of-fit of the final model.

Results
=======

The median age was 39 years (IQR: 30--52) among KTRs while the median age among the control group was 41 years (IQR: 29--48), as shown in [Table 1](#t1-ijnrd-11-187){ref-type="table"}. The most common causes of ESKD in the KTR population were hypertension-attributed CKD and glomerulonephritis (both n = 19, 46.3%).

All the KTRs were on calcineurin inhibitor (CNI)-based immunosuppressive therapy (with more than 90% on Tacrolimus while \<10% were on cyclosporine), antimetabolites (30 \[73.2%\] were on mycophenolate mofetil, five \[12.2%\] were on mycophenolic acid, four \[9.8%\] were on azathioprine, and two \[4.9%\] were on Leflunomide), and 5 mg maintenance prednisone daily. The majority (n = 38/41, 92.7%) of the KTRs had received deceased donor organs while three (7.3%) had related living donor transplantation. The median post-transplant follow-up duration was 4 years (IQR: 1--7) while median pre-transplant dialysis duration was 5 years (IQR: 4--6). LVH was present in 34 (82.9%) of the KTRs; 15/17 (88.2%) of KTRs with GFR \<60 mL/min/173 m^2^ and in 13/18 (72.2%) KTRs with elevated blood pressure. Among the KTRs, 24 (58.5%) had concentric hypertrophy (relative wall thickness \[RWT\] \> 0.42 and left ventricular mass index \[LVMI\] \>95 g/m^2^ for females or \>115 g/m^2^ for males), ten (24.4%) had eccentric hypertrophy (RWT ≤0.42 and LVMI \>95 g/m^2^ for females or \>115 g/m^2^ for males), five (12.2%) had concentric remodeling (RWT \>0.42 and LVMI ≤95 g/m^2^ for females or ≤115 g/m^2^ for males), and two (4.9%) had normal geometry. Using the combination of increased CIMT values (\>0.55 mm) and the presence of plaques, AsVD was present in 19 (46.3%) KTRs compared to seven (17.1%) healthy controls, (*p*=0.004). CIMT was significantly increased among the KTRs compared to the controls (*p*=0.021). As shown in [Table 2](#t2-ijnrd-11-187){ref-type="table"}, significant differences were seen between other echocardiographic measurements when KTRs were compared to controls. There was no association between CNI agents and AsVD, (*χ*^2^ = 1.46, *p* = 0.321).

There was a statistically significant difference in Castelli 1 and 2 indices, AI, non-HDL, and LCI in those with AsVD compared to those without AsVD ([Table 3](#t3-ijnrd-11-187){ref-type="table"}). There were no statistically significant differences in the serum levels of TC, TG, LDL, and HDL. Spearman's correlation between CIMT and risk factors for CVD among KTRs revealed a positive relationship with LVM (*r* = 0.52, *p* \< 0.001), LVH (*r* = 0.53, *p* \< 0.001), LAD (*r* = 0.43, *p* = 0.007), age (*r* = 0.43, *p* = 0.005), and WHR (*r* = 0.39, *p* = 0.012) as shown in [Table 4](#t4-ijnrd-11-187){ref-type="table"}. Of the lipid profile parameters and lipoprotein ratios in KTRs, only Castelli 2 index and LCI showed correlation with CIMT.

The multivariable model of the predictors of AsVD showed that KTR status confers an 11-fold risk of developing AsVD (OR = 11.22, 95% CI = 1.82--68.93, *p* = 0.009); [Table 5](#t5-ijnrd-11-187){ref-type="table"}. The odds of developing AsVD was 17 times higher in subjects ≥40 years (*p* = 0.001). Age and KTR status were independent predictors of AsVD after correcting for WHR, proteinuria, GFR, Castelli index 2, and LVH. The goodness-of-fit of the model was assessed by the Hosmer--Lemeshow test (*p* = 0.319). Binary logistic regression analysis among KTRs showed that age \>40 years independently predicted AsVD after adjusting for post-transplant follow-up duration, duration of dialysis and LVH, [Table 6](#t6-ijnrd-11-187){ref-type="table"}.

Discussion
==========

AsVD was significantly more prevalent among KTRs compared to controls in our study, with nearly half of the KTRs having AsVD. This is comparable with findings from previous studies.[@b17-ijnrd-11-187]--[@b19-ijnrd-11-187] Basiratnia et al[@b17-ijnrd-11-187] demonstrated a higher mean CIMT in KTRs compared to healthy controls. Similarly, Cader et al[@b19-ijnrd-11-187] found a significantly higher prevalence of increased CIMT among their cohort of KTRs. Although the control group in our study and the study by Basiratnia et al[@b17-ijnrd-11-187] were similar, in the study by Cader et al[@b19-ijnrd-11-187] the controls were CKD stage and cardiovascular risk matched. Prevalence of AsVD in our study (46.3%) is very similar to that reported in a previous study by Japichino et al (46.5%).[@b18-ijnrd-11-187] The higher prevalence of AsVD (66.7%) reported by Cader et al[@b19-ijnrd-11-187] could be due to visualization of carotid plaques and measurement of CIMT at the carotid bulb, and also because of differences in participants' profiles with diabetes mellitus accounting for one third of subjects recruited in their study; we had excluded patients with diabetes mellitus and current smokers. The high prevalence of AsVD in our study can be explained by the significant differences in the levels of some established cardiovascular risk factors such as blood pressure, WHR, proteinuria, GFR, LVH, and LAD in KTRs compared to controls.

We found a strong association between AsVD and cardiovascular risk factors. Age, WHR, Castelli indices 1 and 2, non-HDL, AI, LCI, serum fibrinogen levels, LAD, LVH, and mitral valve deceleration time were also significantly associated with the presence of AsVD in our study, comparable to results from previous studies.[@b18-ijnrd-11-187]--[@b24-ijnrd-11-187] Kolonko et al[@b20-ijnrd-11-187] found age, pre-transplant diabetes, LVH, and CVD to be related to CIMT, which is similar to our findings, despite the exclusion of diabetic KTRs from our study based on the known association between diabetes, dyslipidemia, and atherosclerosis.[@b25-ijnrd-11-187] Serum fibrinogen has been shown to increase inflammatory and atherosclerotic conditions, possibly through the elaboration of inflammatory cytokines by macrophages involved in atherosclerosis and subsequent stimulation of fibrinogen production by these cytokines.[@b21-ijnrd-11-187] In our study population, serum fibrinogen was significantly higher among KTRs compared to controls and also significantly higher among participants who had AsVD compared to those without AsVD. AsVD is currently viewed as an inflammatory disease and serum levels of fibrinogen have been influenced by several risk factors of CVD such as hypertension, diabetes, and inflammation.[@b22-ijnrd-11-187],[@b23-ijnrd-11-187] Among a cohort of ESKD patients on chronic hemodialysis, serum fibrinogen was found to be higher among patients with fatal and non-fatal cardiovascular events compared to event-free patients.[@b24-ijnrd-11-187] Our study, which demonstrates an association between AsVD and LVH is supported by reports from an earlier study which described LVH as both a CVD and a risk factor for CVD.[@b26-ijnrd-11-187]

Our study found that age, WHR, Castelli 2, LAD, LVM, and LVMI had positive correlations with CIMT; the association between increased CIMT and age had been described in a previous study.[@b27-ijnrd-11-187] Also, advancing age has been associated with diminished nitric oxide-mediated vasodilatation and reduction in total nitric production, resulting in endothelial dysfunction.[@b28-ijnrd-11-187] Increasing age has also been associated with other risk factors for AsVD such as diabetes, hypertension, and vascular calcification.[@b27-ijnrd-11-187] LVH is an important predictor of all-cause mortality among KTRs.[@b29-ijnrd-11-187] Our study showed a negative correlation between LVH and renal function (*r* = −0.25, *p* = 0.02), consistent with earlier studies in pre-dialysis CKD patients[@b23-ijnrd-11-187] and KTRs.[@b11-ijnrd-11-187] An increased WHR has been associated with cardiovascular events among CKD patients;[@b30-ijnrd-11-187] the finding of a positive correlation between WHR and CIMT in our study is probably due to the use of steroids by the KTRs but may also be explained by the fact that restoration of renal function after kidney transplantation reduces CKD-related inflammation and malnutrition, enhancing appetite and weight gain.

In our study population, among all the lipid profile and lipoprotein indices analyzed, only Castelli 2 index and LCI correlated positively with CIMT. This finding could be due to the aggressive treatment of dyslipidemia with statins in our patients. Sub-analysis within the KTR group showed that Castelli 2 index retained its positive correlation with CIMT (*r* = 0.33 *p* = 0.035) while LDL showed a marginally significant correlation. There was no correlation between blood pressure and CIMT, possibly due to the aggressive blood pressure treatment in our KTRs who had a median blood pressure of 139.7/89.5 mmHg.

Age and KTR status were independent predictors of AsVD even after correcting for WHR, proteinuria, GFR, Castelli index 2, and LVH ([Table 4](#t4-ijnrd-11-187){ref-type="table"}). Among KTRs, only age \>40 years predicted AsVD even when adjusted for LVH, duration of dialysis and post-transplant duration. Increasing age has been demonstrated to be an important predictor of vascular injury[@b28-ijnrd-11-187] and atherosclerosis has been shown to be associated with changes in CIMT early in the post-kidney transplant period.[@b31-ijnrd-11-187]

This study excluded patients with diabetes mellitus, connective tissue diseases and inflammatory disorders, acute and chronic infections, and smokers. Furthermore, only stable, black KTRs were recruited. This could have contributed to the lower prevalence of AsVD seen in this study compared to the other studies alluded to in the discussion.

In conclusion, AsVD is common among KTRs. Strong correlations exist between CIMT and age, WHR, LVH, LAD, ejection fraction, and mitral valve deceleration time. Among the KTRs' lipoprotein indices, namely Castelli index 2 and LCI, showed a better correlation with CIMT than conventional lipid profile parameters. Age and KTR status were independent predictors of AsVD. The findings of this study suggest that serum fibrinogen, Castelli index 2, and LCI may be important surrogate markers of atherosclerosis in KTRs. It is recommended that the levels of these markers be determined before renal transplantation and monitored in the post-transplant period. In addition, we also recommend more aggressive surveillance for AsVD among KTRs older than 40 years of age.
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###### 

Sociodemographic and clinical characteristics of the study population

  Parameter                                  KTR (n = 41) (%)                                              Control (n = 41) (%)
  ------------------------------------------ ------------------------------------------------------------- ----------------------------------------------------------
  Age (years)                                39 (30--52)[\*](#tfn1-ijnrd-11-187){ref-type="table-fn"}      41 (29--48)[\*](#tfn1-ijnrd-11-187){ref-type="table-fn"}
  Sex                                                                                                      
   Female                                    20 (49.0)                                                     23 (56.0)
   Male                                      21 (51.0)                                                     18 (44.0)
  Marital status                                                                                           
   Married                                   23 (56.0)                                                     30 (73.0)
   Single                                    18 (44.0)                                                     11 (27.0)
  Cause of ESKD                                                                                            
   Hypertension                              19 (46.3)                                                     
   Glomerulonephritis                        19 (46.3)                                                     
   Primary oxalosis                          1 (2.4)                                                       
   Dysplastic kidneys                        2 (4.9)                                                       
  Donor source                                                                                             
   Deceased                                  38 (92.7)                                                     
   RLD                                       3 (7.3)                                                       
  CNI                                                                                                      
   Tacrolimus                                37 (90.2)                                                     
   Cyclosporine                              4 (9.8)                                                       
  Pre-transplant dialysis duration (years)   5.0 (4.0--6.0)[\*](#tfn1-ijnrd-11-187){ref-type="table-fn"}   
  Post-transplant duration (years)           4.0 (1.0--7.0)[\*](#tfn1-ijnrd-11-187){ref-type="table-fn"}   
  Proteinuria                                                                                              
   ≤3 mg/mmol                                19 (46.3)                                                     39 (95.1)
   \>3 mg/mmol                               22 (53.7)                                                     2 (4.9)
  Hypertension                                                                                             
   Absent                                    16 (39.0)                                                     34 (82.9)
   Present                                   25 (61.0)                                                     7 (17.1)

**Note:**

Median (interquartile range).

**Abbreviations:** KTR, kidney transplant recipient; ESKD, end-stage kidney disease; RLD, related living donor; CNI, calcineurin inhibitor.

###### 

Comparison of cardiovascular risk factors between kidney transplant recipients and controls

  Parameters                KTR (n = 41)           Control (n = 41)      *p*-value
  ------------------------- ---------------------- --------------------- ------------------------------------------------------
  Age (years)               39 (30--52)            41 (29--48)           0.824[\*](#tfn4-ijnrd-11-187){ref-type="table-fn"}
  BMI (kg/m^2^)             25.7 (23.1--28.5)      28.7 (22.9--31.2)     0.081[\*](#tfn4-ijnrd-11-187){ref-type="table-fn"}
  WHR                       0.89±0.07              0.85±0.06             0.002[\#](#tfn3-ijnrd-11-187){ref-type="table-fn"}
  SBP (mmHg)                139.7±15.8             125.4±11.3            \<0.001[\#](#tfn3-ijnrd-11-187){ref-type="table-fn"}
  MAP (mmHg)                106.9±13.8             94.6±11.4             \<0.001[\#](#tfn3-ijnrd-11-187){ref-type="table-fn"}
  TC (mmol/L)               4.46 (3.93--4.93)      4.27 (3.71--4.70)     0.330[\*](#tfn4-ijnrd-11-187){ref-type="table-fn"}
  LDL (mmol/L)              2.63 (2.15--3.08)      2.59 (2.08--3.17)     0.777[\*](#tfn4-ijnrd-11-187){ref-type="table-fn"}
  TG (mmol/L)               1.31 (1.06--1.92)      1.25 (0.80--1.53)     0.399[\*](#tfn4-ijnrd-11-187){ref-type="table-fn"}
  HDL (mmol/L)              1.29 (1.05--1.47)      1.15 (0.98--1.54)     0.467[\*](#tfn4-ijnrd-11-187){ref-type="table-fn"}
  Urine-ACR (mg/mmol)       4.60 (1.20--16.2)      0.40 (0.20--0.80)     \<0.001[\*](#tfn4-ijnrd-11-187){ref-type="table-fn"}
  Fibrinogen (g/L)          3.00 (2.60--3.5)       2.50 (2.20--3.20)     0.027[\*](#tfn4-ijnrd-11-187){ref-type="table-fn"}
  SCr (µmol/L)              123 (91--152)          80 (63--89)           \<0.001[\*](#tfn4-ijnrd-11-187){ref-type="table-fn"}
  eGFR (mL/min/1.73 m^2^)   71 (49--85)            113 (99--124)         \<0.001[\*](#tfn4-ijnrd-11-187){ref-type="table-fn"}
  LAD (mm)                  35.9 (32.3--34.6)      31.02 (29.0--32.2)    \<0.001[\#](#tfn3-ijnrd-11-187){ref-type="table-fn"}
  CIMT (mm)                 0.60 (0.51--0.66)      0.53 (0.47--0.60)     0.021[\*](#tfn4-ijnrd-11-187){ref-type="table-fn"}
  LVM (g)                   219 (187--284)         174 (142--226)        0.001[\*](#tfn4-ijnrd-11-187){ref-type="table-fn"}
  LVMI (g/m^2^)             130.0 (108.4--165.2)   101.1 (73.8--115.7)   \<0.001[\*](#tfn4-ijnrd-11-187){ref-type="table-fn"}

**Notes:**

Mean ± SD, Student's *t*-test;

median (interquartile range), Wilcoxon rank-sum test.

**Abbreviations:** KTR, kidney transplant recipient; BMI, body mass index; WHR, waist--hip ratios; SBP, systolic blood pressure; MAP, mean arterial pressure; TC, total cholesterol; LDL, low-density lipoprotein; TG, triglyceride; HDL, high-density lipoprotein; urine-ACR, urine albumin--creatinine ratio; SCr, serum creatinine; eGFR, estimated glomerular filtration rate; LAD, left atrial diameter; CIMT, carotid intima media thickness; LVM, left ventricular mass; LVMI, left ventricular mass index.

###### 

Comparison between participants with atherosclerotic vascular disease and without it

  Parameter                 KTRs and controls (n = 82)   *p*-value              KTRs (n = 41)                                           *p*-value                                     
  ------------------------- ---------------------------- ---------------------- ------------------------------------------------------- ---------------------- ---------------------- ---------
  Age (years)               48.0 (41.0--55.0)            32.5 (27.0--44.0)      \< 0.001[\*](#tfn7-ijnrd-11-187){ref-type="table-fn"}   48.0 (39.0--62.0)      30.5 (26.0--40.0)      \<0.001
  WHR                       0.91 (0.86--0.93)            0.86 (0.83--0.90)      0.028[\#](#tfn6-ijnrd-11-187){ref-type="table-fn"}      0.91 (0.88--0.96)      0.87 (0.84--0.90)      0.069
  BMI (kg/m^2^)             26.5 (24.0--31.2)            27.1 (21.5--30.0)      0.273[\*](#tfn7-ijnrd-11-187){ref-type="table-fn"}      26.2 (23.7--28.2)      25.3 (20.7--28.7)      0.513
  SBP (mmHg)                139.2 (132.6--145.9)         140.1 (132.3--147.0)   0.855[\#](#tfn6-ijnrd-11-187){ref-type="table-fn"}      138.0 (128.0--147.0)   141.1 (126.0--151)     0.794
  AIP                       0.03 (-0.03--0.11)           0.02 (-0.08--0.12)     0.729[\*](#tfn7-ijnrd-11-187){ref-type="table-fn"}      0.02 (-0.13--0.20)     0.01 (-0.15--0.22)     0.917
  Castelli 1                4.1 (3.1--4.9)               3.1 (2.5--4.1)         0.033[\*](#tfn7-ijnrd-11-187){ref-type="table-fn"}      3.53 (3.00--4.80)      3.36 (2.57--4.16)      0.403
  Castelli 2                2.5 (1.6--3.2)               1.8 (1.3--2.6)         0.048[\*](#tfn7-ijnrd-11-187){ref-type="table-fn"}      2.09 (1.53--2.73)      1.67 (1.12--2.55)      0.158
  LCI                       15.4 (10.1--18.9)            8.7 (4.4--19.6)        0.013[\*](#tfn7-ijnrd-11-187){ref-type="table-fn"}      13.38 (9.13--16.54)    8.65 (4.61--24.32)     0.308
  Non-HDL                   3.4 (2.8--4.0)               2.9 (2.3--3.5)         0.019[\*](#tfn7-ijnrd-11-187){ref-type="table-fn"}      3.31 (2.76--3.77)      3.03 (2.36--3.76)      0.381
  AI                        3.0 (2.1--3.9)               2.1 (1.5--3.2)         0.034[\*](#tfn7-ijnrd-11-187){ref-type="table-fn"}      2.53 (2.00--3.80)      2.36 (1.57--3.36)      0.403
  TC (mmol/L)               4.5 (4.1--5.1)               4.3 (3.5--4.8)         0.071[\*](#tfn7-ijnrd-11-187){ref-type="table-fn"}      4.46 (4.14--4.93)      4.47 (3.46--5.09)      0.666
  TG (mmol/L)               1.3 (1.1--2.1)               1.3 (0.8--1.7)         0.139[\*](#tfn7-ijnrd-11-187){ref-type="table-fn"}      1.29 (0.99--1.89)      1.32 (1.12--1.95)      0.855
  LDL (mmol/L)              2.7 (2.2--3.3)               2.6 (2.0--2.9)         0.087[\*](#tfn7-ijnrd-11-187){ref-type="table-fn"}      2.65 (2.19--3.24)      2.49 (1.45--2.73)      0.205
  HDL (mmol/L)              1.1 (0.9--1.4)               1.3 (1.1--1.6)         0.163[\*](#tfn7-ijnrd-11-187){ref-type="table-fn"}      1.16 (1.01--1.60)      1.32 (1.09--1.47)      0.456
  Fibrinogen (g/L)          3.0 (2.6--3.5)               2.5 (2.2--3.2)         0.041[\*](#tfn7-ijnrd-11-187){ref-type="table-fn"}      3.00 (2.70--3.60)      2.95 (2.50--3.30)      0.582
  Urine-ACR (mg/mmol)       2.3 (0.8--8.1)               0.8 (0.3--2.6)         0.056[\*](#tfn7-ijnrd-11-187){ref-type="table-fn"}      2.60 (1.40--10.7)      9.65 (1.20--30.8)      0.296
  eGFR (mL/min/1.73 m^2^)   86.5 (54.0--117)             97.5 (70.5--116.0)     0.386[\*](#tfn7-ijnrd-11-187){ref-type="table-fn"}      71.0 (44.0--115.0)     70.0 (49.0--84.0)      0.497
  LAD (mm)                  37.5 (32.0--40.0)            32.0 (29.0--35.0)      \<0.001[\#](#tfn6-ijnrd-11-187){ref-type="table-fn"}    38.0 (35.0--41.0)      34.5 (30.0--36.0)      0.011
  LVMI (g/m^2^)             135.1 (118.2--168.2)         103.9 (81.6--123.5)    \<0.001[\*](#tfn7-ijnrd-11-187){ref-type="table-fn"}    141.2 (128.2--178.0)   116.2 (100.7--131.8)   \<0.001
  Dec. time (ms)            172.5 (155.0--201.0)         148.0 (129.5--171.0)   \<0.001[\*](#tfn7-ijnrd-11-187){ref-type="table-fn"}    176.0 (158.0--204.0)   135.5 (120.0--175.0)   0.003
  EF (%)                    73.0 (64.0--79.0)            68.0 (62.5--74.0)      0.229[\*](#tfn7-ijnrd-11-187){ref-type="table-fn"}      76.0 (64.0--80.0)      69.0 (64.0--79.0)      0.574

**Notes:**

Mean ± SD, Student's *t*-test;

median (interquartile range), Wilcoxon rank-sum test.

**Abbreviations:** KTR, kidney transplant recipient; AsVD, atherosclerotic vascular disease; WHR, waist--hip ratios; BMI, body mass index; SBP, systolic blood pressure; AIP, atherogenic index of plasma; LCI, lipoprotein combine index; HDL, high-density lipoprotein; AI, atherogenic index; TC, total cholesterol; TG, triglyceride; LDL, low-density lipoprotein; urine-ACR, urine albumin--creatinine test; eGFR, estimated glomerular filtration rate; LAD, left atrial diameter; LVMI, left ventricular mass index; Dec. time, mitral valve deceleration time; EF, ejection fraction.

###### 

Correlation of carotid intima media thickness to risk factors for cardiovascular disease among kidney transplant recipients

  Parameter                 KTR (n = 41)   Controls (n = 41)                                              
  ------------------------- -------------- ------------------------------------------------------ ------- -------
  Age (years)               0.42           0.006[\*](#tfn9-ijnrd-11-187){ref-type="table-fn"}     0.24    0.138
  WHR                       0.39           0.013[\*](#tfn9-ijnrd-11-187){ref-type="table-fn"}     −0.13   0.431
  BMI (kg/m^2^)             0.17           0.296                                                  0.11    0.512
  eGFR (mL/min/1.73 m^2^)   0.29           0.071                                                  −0.08   0.617
  TC (mmol/L)               0.20           0.203                                                  0.19    0.230
  LDL (mmol/L)              0.30           0.050                                                  0.08    0.619
  TG (mmol/L)               0.09           0.566                                                  −0.02   0.919
  Castelli 1                0.27           0.082                                                  0.06    0.710
  Castelli 2                0.33           0.035[\*](#tfn9-ijnrd-11-187){ref-type="table-fn"}     0.03    0.845
  AIP                       0.13           0.408                                                  −0.03   0.834
  Non-HDL                   0.29           0.071                                                  0.12    0.465
  Atherogenic index         0.28           0.082                                                  0.06    0.710
  LCI                       0.31           0.047[\*](#tfn9-ijnrd-11-187){ref-type="table-fn"}     0.04    0.813
  EF (%)                    0.32           0.044[\*](#tfn9-ijnrd-11-187){ref-type="table-fn"}     0.06    0.710
  FS (%)                    0.27           0.090                                                  0.02    0.884
  E/e′                      0.21           0.180                                                  0.28    0.079
  Dec. time (ms)            0.59           \<0.001[\*](#tfn9-ijnrd-11-187){ref-type="table-fn"}   0.15    0.341
  LVM (g)                   0.50           \<0.001[\*](#tfn9-ijnrd-11-187){ref-type="table-fn"}   0.24    0.132
  LVMI (g/m^2^)             0.50           \<0.001[\*](#tfn9-ijnrd-11-187){ref-type="table-fn"}   0.25    0.111
  LAD (mm)                  0.42           0.007[\*](#tfn9-ijnrd-11-187){ref-type="table-fn"}     0.14    0.373

**Note:**

Statistically significant, *p*\<0.05.

**Abbreviations:** E/e′, ratio of transmitral doppler early filling velocity to tissue doppler early diastolic mitral annular velocity; KTR, kidney transplant recipient; WHR, waist--hip ratios; BMI, body mass index; eGFR, estimated glomerular filtration rate; TC, total cholesterol; LDL, low-density lipoprotein; TG, triglyceride; AIP, atherogenic index of plasma; HDL, high-density lipoprotein; LCI, lipoprotein combine index; EF, ejection fraction; FS, fractional shortening; Dec. time, mitral valve deceleration time; LVM, left ventricular mass; LVMI, left ventricular mass index; LAD, left atrial diameter.

###### 

Logistic regression showing relationship of atherosclerotic vascular disease to risk factors of cardiovascular disease

  Risk factors               OR      95% CI        *p*-value
  -------------------------- ------- ------------- -----------------------------------------------------
  Age (years)                17.12   3.36--87.12   0.001[\*](#tfn11-ijnrd-11-187){ref-type="table-fn"}
  WHR                        0.56    0.14--2.17    0.401
  GFR (mL/min/1.73 m^2^)     0.34    0.67--1.73    0.193
  Proteinuria                1.29    0.32--5.20    0.720
  Kidney transplant status   11.22   1.82--68.93   0.009[\*](#tfn11-ijnrd-11-187){ref-type="table-fn"}
  Castelli index 2           1.95    0.57--6.73    0.288
  LVH (g/m^2^)               2.49    0.42--14.60   0.312

**Note:**

Statistically significant, *p*\<0.05.

**Abbreviations:** WHR, waist--hip ratios; GFR, glomerular filtration rate; LVH, left ventricular hypertrophy.

###### 

Logistic regression showing relationship of atherosclerotic vascular disease to risk factors among KTRs

  Risk factors                           OR     95% CI        *p*-value
  -------------------------------------- ------ ------------- -----------------------------------------------------
  Age at transplant (\>40 years)         8.54   1.77--41.23   0.008[\*](#tfn13-ijnrd-11-187){ref-type="table-fn"}
  Post-transplant duration (\>3 years)   1.09   0.25--4.81    0.914
  Duration of dialysis (\>3 years)       1.58   0.37--6.80    0.542
  LVH (g/m^2^)                           2.12   0.11--40.53   0.618

**Note:**

Statistically significant, *p*\<0.05.

**Abbreviations:** KTRs, kidney transplant recipients; LVH, left ventricular hypertrophy.

[^1]: These authors contributed equally to this work
